Back to overview

High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Author Chihota Belinda V, Wandeler Gilles, Chilengi Roma, Mulenga Lloyd, Chung Raymond T, Bhattacharya Debika, Egger Matthias, Vinikoor Michael J,
Project Forschungspauschale Forschungsratspräsident SNF
Show all

Original article (peer-reviewed)

Journal The Journal of Infectious Diseases
Volume (Issue) 221(2)
Page(s) 218 - 222
Title of proceedings The Journal of Infectious Diseases

Open Access

Type of Open Access Green OA Embargo (Freely available via Repository after an embargo)


AbstractAmong 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia, median baseline CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive. Within 2 years of therapy, 29 (10.2%) participants experienced HBV functional cure (confirmed loss of hepatitis B surface antigen). In multivariable analysis, baseline CD4 count <350 cells/mm3, female sex, and lower baseline HBV deoxyribonucleic acid were associated with increased odds of functional cure. Immune recovery during HIV-HBV treatment with ART may drive higher rates of functional cure than during HBV monoinfection treatment. Understanding the mechanisms underlying this phenomenon could inform immunomodulatory therapies for HBV cure.